Factors associated with antihypertensive medication use and blood pressure control in a rural area in Bangladesh: baseline data from a cluster randomised control trial

Fakir M. Amirul Islam1,2*, Elisabeth A. Lambert1,3, Sheikh Mohammed Shariful Islam4, M. Ariful Islam2, Ralph Maddison4, Bruce Thompson1 and Gavin W. Lambert1,3

Abstract

Background: The use of antihypertensive medications is critical for controlling high blood pressure. We aimed to investigate associations between socio-demographic factors and antihypertensive medications use, and antihypertensive medications use with different types of drugs use with levels of systolic blood pressure (SBP) and diastolic blood pressure (DBP).

Methods: For the present report we derived data from the baseline measurements of a cluster randomised control trial on 307 participants with previously diagnosed hypertension from the rural district of Naria in Bangladesh. We measured the participant’s current blood pressure levels and recorded antihypertensive medications uses. Associated factors included socio-economic status, diabetes, antihypertensive medications use, and types of drugs and doses used for controlling blood pressure. We applied analysis of variance and logistic regression techniques to identify factors associated with blood pressure.

Results: Of the total participants, 144 (46.9%) were on antihypertensive medications. After multivariate adjustment, binary logistic regression revealed that employees (odds ratio, (95% confidence interval (CI)) (OR 3.58, 95%CI 1.38-9.28) compared to farmers, and people with diabetes (OR 2.43, 95%CI 1.13-5.26) compared to people without diabetes were associated with a higher proportion of antihypertensive medications use. Of 144 participants on antihypertensive medications, 7 (5%) had taken two doses, 114 (79%) had taken one dose per day and the rest were irregular in medication use. The mean (standard deviation) [min, max] SBP and DBP were 149 (19) mmHg [114, 217] and 90 (10) mmHg [75, 126], respectively. Overall, there was no significant difference in SBP (p = 0.10) or DBP (p = 0.67) between participants with or without antihypertensive medications or using any type of medications (p = 0.54 for SBP and 0.76 for DBP). There was no significant association between antihypertensive medications use and elevated BP levels SBP/DBP ≥ 140/90 mmHg (p = 0.42)

Conclusion: Less than half of the people with hypertension were on medication. Irrespective of the antihypertensive medications use, most of the participant’s blood pressure was high. Further study is needed with a large sample to...
understand the factors and aetiology of unmanaged hypertension in rural areas of Bangladesh where the prevalence of hypertension is very high.

**Keywords:** Hypertension, Antihypertensive medications, Factors associated, Rural Bangladesh

**Background**

Hypertension is a major risk factor for disability-adjusted life years and accounts for 19% of deaths or 10.5 million deaths per year worldwide [1–3]. Currently, the estimated prevalence of hypertension is 40% or over 1.1 billion people globally [4]. Lowering blood pressure by 20- mmHg of systolic blood pressure (SBP) or 10-mmHg of diastolic blood pressure (DBP) is associated with a 50% reduction of the risk of a fatal cardiovascular event [5]. Although a significant population with hypertension are unaware of their disease condition, among those with known hypertension, it was estimated that only 18 to 42% of people in high-income countries (HICs) and 8 to 20% in low-income countries were able to control their hypertension [2, 6–10]. Those figures are expected to be disproportionately larger in rural areas where the case fatality due to CVD was also reported to be higher [11].

Previous studies have suggested the prevention and control of hypertension may be improved by the application of targeted and/or population-based strategies. These include interventions to increase awareness in maintaining recommended healthy lifestyle and adherence to antihypertensive medications [10, 12–14], non-adherence to antihypertensive therapy and lifestyle modification are major barriers in managing hypertension [15–17]. Indeed, the prevalence of adherence to antihypertensive medications is estimated to be between 45 and 55% in high-income countries, and 25 to 30% in low-medium income countries. Maintaining medication adherence is a complex issue, especially in patients with chronic diseases where multiple medications and symptoms require attention [18]. Van der Laan et al. [13] noted that non-adherence to antihypertensive medications was associated with a low level of education, low income, younger age, having diabetes, complex medication regimen, multiple dosing regimen, and ethnic variation. Moreover, many patients require aggressive pharmacologic management to control their hypertension [19]. Managing blood pressure at the targeted level is more challenging in low-middle income countries where almost three-quarters of the total hypertension cases reside, and treatment facilities are insufficient [9].

Bangladesh is a low-middle income country with a large population confronting a significant increase in chronic diseases including hypertension [20, 21]. A systematic review and meta-analyses based on 305,432 participants from 53 studies in Bangladesh reported a wide range of hypertension prevalence, ranging from 1 to 75%. The pooled prevalence was reported to be 41% with a cut-off value of ≥130/80 mmHg and/or use of antihypertensive medications [21]. Islam et al. conducted a cross-sectional study among adults aged ≥30 years in a rural area and reported that 40% of adults had hypertension, of which 82% were previously undiagnosed [22]. In a cross-sectional study on people aged 40 years or older in rural communities in Bangladesh, Pakistan and Sri Lanka, Jafar et al. [23] reported that in 53% of people with hypertension in Bangladesh, 71% of people with hypertension in Pakistan and 56% of people with hypertension in Sri Lanka blood pressure remained uncontrolled. Alam et al. [24] conducted a longitudinal study on patients with hypertension and reported that only 37% of rural patients compared to 77% of urban patients visited medically qualified practitioners and that these visits were associated with a mean reduction of 3.3/2.0 (SBP/DBP) mmHg. This indicated that a significant proportion of people with hypertension are unable to control their blood pressure at the targeted level, and that there is a significant gap in service facilities between urban and rural areas. However, the studies had not reported the proportion of patients who were on antihypertensive medications or if the antihypertensive medications were sufficient to control their blood pressure at the targeted level.

The objectives of this study were twofold:

(i) to gain insight into the factors associated with antihypertensive medications use, and
(ii) to determine the current level of blood pressure and examine its association with antihypertensive medication use in a homogenous group of people with diagnosed hypertension.

**Study participants**

The study consisted of 307 participants aged 30-75 years recruited for a cluster randomized control trial to estimate blood pressure changes due to lifestyle modification intervention from the Banshgram Union in the Narail District of Bangladesh. The study location is situated approximately 200 km away from the capital city Dhaka.

We selected the study population from the previous cross-sectional study, the Bangladesh Population-based Diabetes and Eye Study, conducted in 2013 in Banshgram among adults aged 30-89 years [22, 25]. In this study, 1242 (40%) participants were identified as having hypertension.
agreed to provide written consent. In the source population advanced CVDs or severe health problems or had not received treatment of hypertension. We excluded people who had a history of taking antihypertensive medications [29]. If the proportion of antihypertensive medications use in the current sample would be between 20 to 30%, the sample size was adequate with a statistical power greater than 90% and a significance level of 0.01.

Outcome variable
The outcome measures were as follows:

1. Primary outcome: Systolic and diastolic blood pressure. We measured blood pressure from the right arm with the person sitting upright and took the second measurement after at least 5 minutes of rest and took the average of the two measures. We took the third measure only if the difference between the first and second measures was more than 20%. In that case, we took the average from the two closest readings. We measured blood pressure using a calibrated Omron Premium Blood Pressure Monitor Device, Omron HEM-7322.

2. Secondary outcome: Use of antihypertensive medications. We asked the participants if they were taking any antihypertensive medications during data collection, which was categorized as “yes” or “no”. If they responded “yes”, data collectors checked their prescriptions to record the types of medicine. Medicines were categorized into five major categories: Amlodipine: Calcium Channel Blocker, Atenolol: Beta-blocker, Amlodipine & Atenolol, Losartan: Angiotensin Receptor Blocker (ARBs), and Amlodipine and Losartan combined. The dose of the medication was recorded, and the frequency was categorized as “once per day”, “twice per day” and “irregular use”.

Baseline data collection and cluster RCT
The ORCD investigators, along with four trained data collectors, obtained data from face-to-face interviews. The data collectors, the local investigator and a physician, participated in four zoom meetings organized by the chief investigator to be trained in data collection. Before the main data collection period, we conducted a pilot study to familiarize the data collectors with all study procedures and allow for an optimal flow of participants. After baseline data collection, we divided the study location into two clusters with 156 participants from cluster 1, approximately 50% of the study location comprising nine villages. The other 151 participants were from cluster 2; the remaining location consisted of the remaining nine villages.

Exposure variables
Exposure variables were age, gender, the highest level of education – categorized as no schooling, primary to high school (grade 1 to 9), secondary or higher secondary school certificates (grade 10 to 12 pass), and Bachelor or Master, socio-economic status– categorized as poor, and middle class or rich which was assessed according to Cheng et al. [30]. We categorised the occupation as a housewife, self-managed business, labourers which include digging soils, pulling rikshaw or any laborious works, and employees who include government and non-government employees. Self-reported use of tobacco categorised as “current smoker” and “non-smoker”, and self-reported diabetes status categorised as “no diabetes”, “with diabetes” and “unknown diabetes” were also used as exposure variables. Secondary outcomes included antihypertensive medications use, doses of medication and medication types were also used as exposure variables in estimating their effects on blood pressure.
Statistical analysis
We reported the characteristics of participants, including age, level of education and occupation, using descriptive statistics. We used binary logistic regression techniques to estimate the odds ratio (OR) with its 95% confidence intervals (CI) for antihypertensive medication use associated with socio-demographic factors. The reference categories included men for sex, age 30-39 years for age group, and no education level for level of education. The reference groups are shown in the results section. We selected reference categories for categorical variables, assuming that the other categories were on antihypertensive medication at a higher rate than the reference categories. For example, 30-39 years was the reference group for age categories assuming that 40-49 or any older age categories were on antihypertensive medication at a higher rate. Similarly, in the case of SES, poor was the reference category assuming that middle class or rich people were on antihypertensive medication at a higher rate. The lower limit of a 95% CI value greater than or equal to 1.0 for any odds ratio greater than 1.0 indicates significantly higher odds of having an attribute than a factor’s reference group. We presented data as mean with standard deviation (SD) and minimum and maximum value of SBP and DBP by socio-demographic and other factors including antihypertensive medications use, types and dose of medication. We analyzed this using one-way ANOVA. Chi-square test of association was used to report if there was any association between medication use and elevated BP with the cut-off of ≥140/90 mmHg [31]. Statistical software SPSS (SPSS Inc, version 27) was used for the analysis.

Results
The cohort comprised an almost equal number of men and women, one-third of the participants were over 60 years of age and 15% were between 30-39 years of age, one-third of the participants had no schooling, half of the participants were homemakers, about one-fifth of the participants were farmers and another one-fifth were employees, one-fifth of the participants were current smokers (Table 1). There was no significant difference in sociodemographic characteristics between the control and the intervention group (Table 2).

In the total sample, the measure of SBP was mean ± SD [minimum, maximum] 149± 19 [114, 217] mmHg and DBP was 90±10 [75, 126] mmHg. Overall, age (p = 0.002 for trend), level of education (p = 0.04) and socio-economic status (0.05) were significantly associated with SBP.

The proportion of people on antihypertensive medications was 46.9% (n = 144), which was significantly higher in people of age 50-59 years (odds ratio (OR) (95% Confidence Interval (CI)): 2.11 (1.01, 4.41)) and 60-69 years (OR (95% CI): 2.88 (1.35, 6.17)) compared to age 30-39 years. After multivariate adjustment, employees (OR (95%CI): 4.06 (1.87, 8.83) compared to farmers, and people with diabetes OR (95% CI): 2.14 (1.06, 4.29) compared to people with no diabetes were associated with a higher proportion of antihypertensive medications use. Level of education, socio-economic status or smoking status was not associated with a higher proportion of antihypertensive medications use (Table 3).

In the total subjects, the measure of SBP was mean ± SD [minimum, maximum] 149± 19 [114, 217] mmHg and DBP was 90±10 [75, 126] mmHg. Overall, age (p = 0.002 for trend), level of education (p = 0.04) and socio-economic status (0.05) were significantly associated with higher SBP. Participants of age 30-39 years had significantly lower SBP 141±12 [123, 178] compared to those 50 years or older, such as for 50-59 years of age SBP was 149±19 [114, 205]. No education 152±17 [125, 208] compared to any levels of education, and being poor 150±20 [114, 205] compared to the middle class or above were associated with significantly higher mean SBP. Tobacco smoking was not associated with either SBP or DBP. None of the factors was associated with DBP.

There was no difference in between SBP or DBP in those taking or not taking antihypertensive medications. Medication type and the dose taken was not associated with SBP or DBP (Table 4).

Of participants who were on medication, 73% had elevated BP (≥140/90 mmHg) compared to 69% who were not on antihypertensive medication (p = 0.42). Although there was no significant association between types of medication and blood pressure, atenolol was associated with the highest proportion of individuals with elevated BP (86.4%), and the combination of amlodipine & losartan had the lowest proportion with elevated BP (46.7%) (p = 0.10) (Table 5).

Discussion
In this study we report the prevalence of antihypertensive medication use, doses of medication and their association with current blood pressure level in people with previously diagnosed hypertension in a typical rural area in Bangladesh where the prevalence of hypertension has been shown to be 41% [32]. The significant findings from this study include: (1) that less than half of the participants previously diagnosed with hypertension were currently on medication, (2) employees and patients with diabetes were more likely to be on medication, (3) higher education and younger age was associated with lower level of systolic blood pressure (4) almost two-thirds of the participants had blood pressure ≥140/90 mmHg.
SBP/DBP, and (5) the use of medication was not shown to be associated with achieving BP level <140/90 mmHg.

In the current study, the association of higher education and younger age with a lower level of blood pressure is consistent with previous studies [33–35]. Association of higher education with lower level of blood pressure may be due to educated people being more aware of managing health and adhere to regularity in treatment follow-up or taking regular physical exercise [34], and that they can afford medications compared to people with a low level of education who work in lower paying employment. This is supported by our findings that employees were significantly associated with a higher proportion of taking medication than those who worked in lower-paying employment, higher education was also shown to have an upward trend in taking antihypertensive medications. Vargas et al. [35] have reported that people with education level 12 years or higher among non-Hispanic Whites who were younger than 25-44 years of age was associated with a lower incidence of hypertension both in men and women compared to those with a lower level of education. We have found that there was an association between being older and a higher level of blood pressure. Higher level of blood pressure among older people can be partly because BP is more difficult

### Table 1 Socio-demographic characteristics, smoking status, diabetes, antihypertensive medications use for the total participants from a cluster RCT in a rural area in Bangladesh

|                        | Number | Percentage |
|------------------------|--------|------------|
| **Sex**                |        |            |
| Female                 | 154    | 50.2       |
| Male                   | 153    | 49.8       |
| **Age group, years**   |        |            |
| Below 40               | 46     | 15.0       |
| 40-49                  | 65     | 21.2       |
| 50-59                  | 95     | 30.9       |
| 60-69                  | 79     | 25.7       |
| 70 or older            | 22     | 7.2        |
| **Level of education** |        |            |
| No education           | 99     | 32.4       |
| Primary to high school | 148    | 48.4       |
| SSC or HSC             | 43     | 14.1       |
| Bachelor or Masters    | 16     | 5.2        |
| **SES**                |        |            |
| Poor or very poor      | 92     | 30.1       |
| Middle class           | 214    | 69.9       |
| **Occupation**         |        |            |
| Housewife              | 146    | 50.5       |
| Business               | 24     | 8.3        |
| Labour                 | 7      | 2.4        |
| Farmer (Agriculture)   | 59     | 20.4       |
| Employees (govt. or private) | 53 | 18.3 |
| **Tobacco smoking**    |        |            |
| Non-smoker             | 245    | 79.8       |
| Current smoker         | 62     | 20.2       |
| **Diabetes status**    |        |            |
| No diabetes            | 217    | 70.7       |
| Diabetes               | 41     | 13.4       |
| Unknown                | 49     | 16.0       |
| **Medication use**     |        |            |
| No medication          | 163    | 53.1       |
| Medication             | 144    | 46.9       |
| **Medication types**   |        |            |
| Amlodipine: Calcium channel blocker | 32 | 22.2 |
| Atenolol: Beta blocker  | 22     | 15.3       |
| Amlodipine & Atenolol  | 27     | 18.8       |
| Losartan: Angiotensin II receptor blockers (ARBs) | 23 | 16.0 |
| Amlodipine & Losartan  | 15     | 10.4       |
| **Medication dose**    |        |            |
| Twice per day          | 7      | 4.9        |
| Once per day           | 114    | 79.2       |
| Irregular              | 23     | 16.0       |

* percentage based on the denominator of who are on medication
to manage among this vulnerable group, and this is consistent with a previous finding [36].

In the present study we relied on self-reported medication use by checking of medication prescriptions. Our findings are consistent with previous studies which reported that non-adherence to antihypertensive medication to occur between 30 and 50% [33, 34]. A study of self-reported medication use compared with pharmacy records, especially for statins use, calcium channel blockers, β-blockers, and bisphosphonates among older women [37], showed almost perfect agreement. In terms of medication taken, a multicentre study of hypertension, its awareness, treatment and control among older adults in India and Bangladesh [29] reported that 38% of participants had taken antihypertensive treatment in urban, and 22% in rural settings. In our study, 44% of participants were on medication and 73% of participants had elevated blood pressure, as indicated by clinic BP ≥140/90 mmHg [31], which is broadly consistent with studies in other low-middle income countries, such as was reported in the PURE study [38], which reported elevated blood pressure was 52.8% in Bangladesh, 70.6% in

| Table 2 | Socio-demographic characteristics, smoking status, diabetes, antihypertensive medications use for the total participants and by the intervention status from a cluster RCT in a rural area in Bangladesh |
|---------|---------------------------------------------------------------|
|         | Total, N = 307 | Control, N = 156 | Intervention, N = 151 | P  |
|         | Number | % | n | % | n | % |
| Sex     | Female  | 154 | 50.2 | 74 | 47.4 | 80 | 53.0 | 0.33 |
|         | Male    | 153 | 49.8 | 82 | 52.6 | 71 | 47.0 |
| Age group, years | | | | | | | |
| 30-39   | 46      | 15.0 | 19 | 12.2 | 27 | 17.9 | 0.19 |
| 40-49   | 65      | 21.2 | 35 | 22.4 | 30 | 19.9 |
| 50-59   | 95      | 30.9 | 53 | 34.0 | 42 | 27.8 |
| 60-69   | 79      | 25.7 | 42 | 26.9 | 37 | 24.5 |
| 70-75   | 22      | 7.2  | 7  | 4.5  | 15 | 9.9  |
| Level of Education | | | | | | | |
| No education | 99 | 32.4 | 48 | 30.8 | 51 | 34.0 | 0.52 |
| Primary to high school | 148 | 48.4 | 75 | 48.1 | 73 | 48.7 |
| SSC or HSC | 43 | 14.1 | 22 | 14.1 | 21 | 14.0 |
| Bachelor or Masters | 16 | 5.2  | 11 | 7.1  | 5  | 3.3  |
| SES | | | | | | | |
| Poor or very poor | 92 | 30.1 | 51 | 32.7 | 41 | 27.3 | 0.31 |
| Middle class | 214 | 69.9 | 105 | 67.3 | 109 | 72.7 |
| Occupation | | | | | | | |
| Housewife | 146 | 49.6 | 71 | 45.7 | 75 | 49.7 |
| Business | 24 | 8.3  | 11 | 7.1  | 7  | 4.5  |
| Labour | 7 | 2.4  | 3 | 2.0  | 4 | 2.6  |
| Farmer (Agriculture) | 59 | 20.1 | 10 | 6.6  | 49 | 32.7 |
| Employees | 53 | 17.5 | 12 | 7.8  | 41 | 27.3 |
| Tobacco smoking | | | | | | | |
| Non-smoker | 245 | 79.8 | 122 | 79.7 | 123 | 81.8 |
| Current smoker | 62 | 20.2 | 23 | 14.6 | 39 | 26.2 |
| Diabetes status | | | | | | | |
| No diabetes | 217 | 70.7 | 122 | 79.2 | 95 | 63.3 |
| Diabetes | 41 | 13.4 | 25 | 16.7 | 16 | 10.7 |
| Unknown | 49 | 16.0 | 22 | 14.1 | 27 | 17.3 |
| Medication use | | | | | | | |
| No medication | 163 | 53.1 | 87 | 56.6 | 76 | 50.3 |
| Medication | 144 | 46.9 | 68 | 43.4 | 78 | 49.7 |
| Medication types | | | | | | | |
| Amlodipine: Calcium channel blocker | 32 | 22.2 | 15 | 25.0 | 7 | 11.9 | 0.08 |
| Atenolol: Beta blocker | 22 | 15.3 | 10 | 16.7 | 12 | 8.0 |
| Amlodipine & Atenolol | 27 | 18.8 | 9 | 15.0 | 18 | 12.0 |
| Losartan: Angiotensin II receptor blockers (ARBs) | 23 | 16.0 | 6 | 10.0 | 17 | 11.3 |
| Amlodipine & Losartan | 15 | 10.4 | 4 | 6.7 | 11 | 7.3 |
| Medication dose | | | | | | | |
| Twice per day | 7 | 4.9  | 4 | 5.8  | 3 | 2.0 |
| Once per day | 114 | 79.2 | 55 | 79.7 | 59 | 78.7 |
| Irregular | 23 | 16.0 | 10 | 14.5 | 13 | 8.3 |

* percentage based on the denominator of who were on medication
Pakistan and 56.5% in Sri Lanka [23]. Another multicentred study in India and Bangladesh reported that among treated patients, 31.9% had elevated BP in the urban setting and 53.6% had elevated BP in the rural setting [29].

Previous studies have demonstrated a clear association between blood pressure control and lifestyle factors, including diet and exercise, ageing, obesity, family history, low salt intake and physical activity [39–43]. Activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system have been implicated in initiating and sustaining blood pressure elevation and are targets for therapy [44]. Indeed, anti-hypertensive medication [45, 46] has consistently been associated with lowering blood pressure. Our study reported that there was no difference in managing blood pressure in people who were and who were not on medications. This could be due to a reason of non-adherence to antihypertensive medications, which is one of the most important factors of uncontrolled blood pressure [13]. In our study, information on medication use was self-report and we did not have any measure of participants actually taking their medications, such as visual inspection or urine analysis of drug metabolites. A study in Germany provided some evidence that increased uptake of polytherapy has increased the BP control rate from 42 to 72% in a decade [46]. However, in our study, less than 50% of the participants who were on medications, three-quarters of these took one dose, 5% of them had taken 2 medications per day and the rest were irregular. This result of taking one dose is consistent with a previous finding conducted in South Asia which reported that 67% of patients took one medication and this was not associated with controlled blood pressure [23]. In the SPRINT study, it was reported that patients required one additional medication to reach the targeted BP compared to those who had uncontrolled BP in the treated group [47]. In the current study, one-third of the people younger than 40 years were on medication compared to more than 50% of those aged 60 years or older, and the mean blood pressure was significantly higher among the older people. This indicates, in older age or people with elevated BP, more aggressive pharmacologic management or personalised patient care may be required to control BP at the targeted level [19].

| Table 3 | Antihypertensive medications use, and its association with sociodemographic, occupation, smoking and diabetes status using logistic regression from a cluster RCT in a rural area in Bangladesh |
|---------|-------------------------------------------------------------------------------------------------|
|                     | No at risk | N (%) | OR (95% CI) a | OR (95% CI) b |
| Total               | 307        | 144 (46.9) | 1.0 (ref.) | 1.0 (ref.) |
| Sex                 |            |         |               |               |
| Male                | 153        | 60 (39.2) | 1.0 (ref.) | 1.0 (ref.) |
| Female              | 154        | 84 (54.5) | 1.86 (0.18, 2.93) | 1.86 (0.18, 2.93) |
| Age (years)         |            |         |               |               |
| 30–39               | 46         | 15 (32.6) | 1.0 (ref.) | 1.0 (ref.) |
| 40–49               | 65         | 25 (38.5) | 1.29 (0.58, 2.86) | 1.29 (0.58, 2.86) |
| 50–59               | 95         | 48 (50.5) | 2.11 (1.01, 4.41) | 2.11 (1.01, 4.41) |
| 60–69               | 79         | 46 (58.2) | 2.88 (1.35, 6.17) | 2.88 (1.35, 6.17) |
| 70–75               | 22         | 10 (45.5) | 1.72 (0.61, 4.88) | 1.72 (0.61, 4.88) |
| Level of education  |            |         |               |               |
| No education        | 99         | 47 (47.5) | 1.0 (ref.) | 1.0 (ref.) |
| Primary to high school | 148      | 70 (47.3) | 0.99 (0.60, 1.65) | 1.35 (0.76, 2.42) |
| SSC or HSC          | 43         | 20 (46.5) | 0.96 (0.47, 1.97) | 1.77 (0.74, 4.2) |
| Bachelor or Masters | 16         | 6 (37.5)  | 0.66 (0.22, 1.97) | 1.71 (0.44, 6.61) |
| SES                 |            |         |               |               |
| Poor                | 92         | 41 (44.6) | 1.0 (ref.) | 1.0 (ref.) |
| Middle class or rich | 214      | 103 (48.1) | 1.15 (0.71, 1.89) | 1.24 (0.73, 2.12) |
| Occupation          |            |         |               |               |
| Farmer              | 66         | 17 (25.8) | 1.0 (ref.) | 1.0 (ref.) |
| Housewife           | 146        | 80 (54.8) | 3.49 (1.84, 6.63) | 5.09 (0.86, 30.2) |
| Employees           | 53         | 31 (58.5) | 4.06 (1.87, 8.83) | 3.58 (1.38, 9.28) |
| Business            | 24         | 7 (29.2)  | 1.19 (0.42, 3.35) | 1.23 (0.40, 3.84) |
| Tobacco smoking     |            |         |               |               |
| Non-smoker          | 245        | 117 (47.8) | 1.0 (ref.) | 1.0 (ref.) |
| Current smoker      | 62         | 27 (43.5) | 0.84 (0.48, 1.48) | 1.73 (0.82, 3.64) |
| Diabetes status     |            |         |               |               |
| No diabetes         | 217        | 103 (47.5) | 1.0 (ref.) | 1.0 (ref.) |
| Diabetes            | 41         | 27 (65.9) | 2.14 (1.06, 4.29) | 2.43 (1.13, 5.26) |
| Unknown             | 49         | 14 (28.6) | 0.44 (0.23, .87) | 0.57 (0.28, 1.16) |

a Odds ratio (OR) (95% confidence interval (CI)): Unadjusted
b OR (95% CI) adjusted for the variables in the model except for sex and age
Table 4  Blood pressure as the outcome variable by socio-demographic, behavioural factors, antihypertensive medications use, and dose of medication as exposure using one-way ANOVA from a cluster RCT in a rural area in Bangladesh

| Total participants | Systolic blood pressure (SBP) | Diastolic blood pressure (DBP) |
|--------------------|-------------------------------|-------------------------------|
|                    | No at risk | Mean ± SD [Min, Max] | P* | Mean ± SD [Min, Max] | P* |
| Total              | 307        | (149±19) [114, 217] |     | (90±10) [75, 126] |     |
| Sex                |            |                    |     |                     |     |
| Female             | 154        | (150±17) [116, 205] | 0.08 | (90±9) [75, 118] | 0.54 |
| Male               | 153        | (148±20) [114, 217] |     | (89±10) [75, 126] |     |
| **Age (years)**    |            |                    |     |                     |     |
| 30-39 a            | 46         | (141±12) [123, 178] | 0.002 | (90±8) [78, 118] | 0.87 |
| 40 - 49 b          | 65         | (147±15) [128, 210] |     | (91±9) [76, 126] |     |
| 50 - 59 b          | 95         | (149±19) [114, 205] |     | (90±9) [75, 117] |     |
| 60 - 69 b          | 79         | (152±21) [114, 217] |     | (89±11) [75, 126] |     |
| 70-75 b            | 22         | (158±22) [112, 208] |     | (89±11) [75, 118] |     |
| **Education**      |            |                    |     |                     |     |
| No education a     | 99         | (152±17) [125, 208] | 0.04 | (90±9) [75, 118] | 0.96 |
| Primary to high school a | 148 | (147±19) [114, 217] |     | (90±10) [75, 126] |     |
| SSC or HSC a       | 43         | (150±18) [123, 198] |     | (90±9) [77, 126] |     |
| Bachelor or Masters b | 16     | (140±16) [130, 196] |     | (89±8) [75, 105] |     |
| SES                |            |                    |     |                     |     |
| Poor               | 92         | (150±20) [114, 205] | 0.05 | (90±10) [76, 118] | 0.12 |
| Middle class       | 214        | (148±18) [114, 217] |     | (90±10) [75, 126] |     |
| Occupation         |            |                    |     |                     |     |
| Housewife          | 146        | (150±17) [116, 205] | 0.43 | (90±9) [75, 118] | 0.48 |
| Business           | 24         | (149±20) [119, 210] |     | (92±12) [77, 126] |     |
| Labour             | 7          | (142±9) [131, 154] |     | (89±8) [78, 98] |     |
| Farmer             | 59         | (146±19) [114, 217] |     | (88±10) [75, 121] |     |
| Employees          | 53         | (150±21) [114, 208] |     | (89±10) [75, 118] |     |
| Tobacco smoking    |            |                    |     |                     |     |
| Non-smoker         | 245        | (149±18) [116, 217] | 0.34 | (90±10) [75, 126] | 0.66 |
| Current smoker     | 62         | (147±20) [114, 210] |     | (89±10) [75, 126] |     |
| Diabetes status    |            |                    |     |                     |     |
| No diabetes        | 217        | (149±20) [114, 217] | 0.43 | (90±10) [75, 126] | 0.43 |
| Diabetes           | 41         | (151±18) [125, 208] |     | (89±10) [75, 118] |     |
| Unknown            | 49         | (146±14) [121, 191] |     | (89±9) [75, 113] |     |
| Medication use     |            |                    |     |                     |     |
| No medication      | 163        | (147±16) [123, 198] | 0.10 | (90±9) [75, 126] | 0.67 |
| Antihypertensive medications | 144 | (151±21) [114, 217] |     | (90±10) [75, 126] |     |
| Medication type    |            |                    |     |                     |     |
| Amlodipine: Calcium channel blocker | 32 | (147±18) [124, 205] | 0.54 | (90±7) [75, 105] | 0.76 |
| Atenolol: Beta blocker | 22 | (147±15) [129, 177] |     | (90±6) [80, 101] |     |
| Amlodipine & Atenolol | 27     | (153±19) [130, 210] |     | (91±13) [75, 126] |     |
| Losartan: Receptor blocker (ARBs) | 23 | (152±23) [116, 200] |     | (88±10) [75, 115] |     |
| Amlodipine & Losartan | 15 | (144±25) [114, 208] |     | (92±14) [76, 118] |     |
| Medication dose    |            |                    |     |                     |     |
| Twice per day      | 7          | (150±28) [114, 193] | 0.53 | (96±15) [76, 118] | 0.28 |
| Once per day       | 114        | (150±20) [116, 210] |     | (90±10) [75, 126] |     |
| Irregular          | 23         | (155±25) [114, 217] |     | (91±10) [79, 121] |     |

*P indicates significance levels

** the same letter indicates no significant difference
between types of medication use and elevated BP levels, atenolol was associated with the highest proportion of individuals with elevated BP and amlodipine and losartan combined with the lowest proportion of elevated BP which is consistent with the findings that at least two antihypertensive drugs are required for most hypertensive patients to achieve BP at targeted level [48].

National guidelines for the management of hypertension in Bangladesh were prepared in 2013 [49]. The policy defined hypertension with a blood pressure cut-off of 140/90 mmHg or higher. Several recommendations were made for managing hypertension, such as maintaining BMI between 18.5-23.5 kg/m², consumption of salt intake <5 gm/day and undertaking moderate-intensity physical activity for at least 30 minutes on most days. Initiation of pharmacotherapy was advised for individuals with stage 1 hypertension, with follow up and use of additional classes of medications for those with higher pressures or if management to target pressure was not achieved. Our study indicated that half of the people with elevated BP were on medication and took only one dose. There are several barriers to lowering BP at an individual and community level, such as having a low level of education, reduced health literacy, low income and, in some jurisdiction, female gender, especially in low-middle income countries [13]. Health inequities may be more evident in rural areas where healthcare facilities, adequate infrastructure, availability of trained clinicians are very different compared to the urban setting [50].

Our study has several strengths: Firstly, the face-to-face data collection from a sample based on their previous participation in a cross-sectional study. The sample consists of almost 50% of women and from a homogenous group across different occupations, age and level of education. However, the study is not free from limitations. Firstly, the recruitment is from a cluster RCT which was not necessary to have a large sample, and thus the sample size limits many sub-analyses and, in some cases, failed to show significant p values although the effect sizes are large. Secondly, the study was conducted in one rural location. Therefore, the results cannot be generalised at the national level. However, the rural population and the health system are very similar in Bangladesh. Finally, medication data was based on self-report and the medication package check and not based on more precise indicators such as visual observation of medications being taken or analysis of urinary medication metabolites.

Conclusions
Our study has provided information on antihypertensive medication use and its association with blood pressure levels in rural Bangladesh. Less than half of the previously diagnosed participants with hypertension were currently on antihypertensive medications. Of people who are on medication, three-quarters took one medication. Almost three-quarters of the participants with previously diagnosed hypertension have elevated BP irrespective of whether they were on medication or not.

Abbreviations
ORCD: Organisation for Rural Community Development; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; CI: Confidence Interval; CVD: Cardiovascular Disease; OR: Odds Ratio; ANOVA: Analysis of variance.

### Table 5 Association of antihypertensive medication use, medication type and dose with people who were able to manage their blood pressure at <140/90 mmHg level using Chi-square tests

|                                | <140/90 mmHg level, number (%) | ≥140/90 mmHg level, number (%) | P*  |
|--------------------------------|--------------------------------|--------------------------------|-----|
| **Total**                      | 90 (29.3)                      | 217 (70.7)                     |     |
| **Medication status**          |                                |                                |     |
| No antihypertensive medication | 51 (31.0)                      | 112 (69.0)                     | 0.42|
| Antihypertensive medications   | 39 (27.0)                      | 105 (73.0)                     |     |
| **Antihypertensive medications types** |                        |                                |     |
| Amlodipine: Calcium channel blocker | 10 (31.3)                      | 22 (68.8)                      | 0.10|
| Atenolol: Beta blocker          | 3 (13.6)                       | 19 (86.4)                      |     |
| Amlodipine & Atenolol          | 6 (22.2)                       | 21 (77.8)                      |     |
| Losartan: Receptor blocker (ARBs) | 6 (26.1)                      | 17 (73.9)                      |     |
| Amlodipine & Losartan          | 8 (53.3)                       | 7 (46.7)                       |     |
| **Medication dose**            |                                |                                |     |
| Twice per day                  | 2 (28.6)                       | 5 (71.4)                       | 0.99|
| Once per day                   | 31 (27.2)                      | 83 (72.8)                      |     |
| Irregular                      | 6 (26.1)                       | 17 (73.9)                      |     |

*p for associations between BP status and medication and dose use
Acknowledgements
We acknowledge the contribution of Md Rafiqul Islam, Md Helal Biswas, Md Sajibul Islam, Md Mofiz Biswas and Md Abidul Islam for their hard work in contacting participants and door-to-door data collection. Finally, we would like to express our gratitude to the study participants for their voluntary participation.

Authors’ contributions
FMAI, EAL and BT designed the study. MAI contributed in data collection and conducting research at the field levels. FMAI analysed the data and drafted the manuscript along with GWL. BT, SM SI and RM ≤ critically reviewed and contributed to the development of the manuscript. All authors approved the final version for publication.

Funding
The School of Health Science of the Swinburne University Technology had provided funds for data collection for this research project. The funders had no role in data collection, analysis or writing manuscripts.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study was conducted following the tenets of the Declaration of Helsinki and was approved by the Swinburne University of Technology Human Research Ethics Committee (Review reference: 20202723-5020). The ethics application was approved on 11 November 2020. Participants were provided with written information about the project and were able to discuss the project with local investigators. For those who were unable to read or illiterate, information was verbally supplied. Informed consent was obtained from all subjects and, if subjects were illiterate or unable to read, informed consents were obtained from a legal guardian on their behalf. None of the participants was below 18 years of age. Participants were informed that they had full rights to withdraw from the study at any stage if they wished and that their decision to participate or not would not influence their relationship with ORCD.

Consent for publication
Written consent was obtained from participants who were able to sign, and a cross mark was obtained from those who were unable to sign. In the case of cross-signed consent, the data collector provided a countersignature for the participants.

Competing interests
The authors declare that they have no competing interests.

Author details
1 School of Health Sciences, Swinburne University of Technology, Hawthorn, VIC 3122, Australia. 2 Organisation for Rural Community Development (ORCD), Dariapur, Narail, Bangladesh. 3 Present Address: Iverson Health Innovation Research Institute, Swinburne University of Technology, Hawthorn, VIC 3122, Australia. 4 Institute for Physical Activity and Nutrition (IPAN), Faculty of Health, Deakin University, Burwood, VIC 3125, Australia.

Received: 7 April 2021  Accepted: 3 December 2021
Published online: 23 December 2021

References
1. Collaborators GBDRF. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1923–94.
2. WHO. Cardiovascular disease: a global brief on hypertension. WHO reference number: WHO/DCO/WHD/2013.2. 2013.
3. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adar-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2294–302.
4. Collaboration NCDRF. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389(10064):37–55.
5. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.
6. Head GA, Shaw JE, Dunstall HW, Owen N, Magliani DJ, Chadban S, et al. Hypertension, white-coat hypertension and masked hypertension in Australia: findings from the Australian Diabetes, Obesity, and Lifestyle Study 3. J Hypertens. 2019;37(8):1615–23.
7. Arokiasamy P, Uttamacharya, Kowal P, Capistrant BD, Gildner TE, Thiele E, et al. Chronic noncommunicable diseases in 6 low- and middle-income countries: findings from wave 1 of the World Health Organization’s Study on Global Ageing and Adult Health (SAGE). Am J Epidemiol. 2017;185(6):414–28.
8. Geldsetzer P, Manne-Goehler J, Marcus ME, Ebert C, Zhumadirov Z, Wesseh CS, et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults. Lancet. 2019;394(10199):652–62.
9. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–50.
10. Dorans KS, Mills KT, Liu Y, He J. Trends in prevalence and control of hypertension according to the 2017 American College of Cardiology/ American Heart Association (ACC/AHA) guideline. J Am Heart Assoc. 2018;7(11):e008888. https://doi.org/10.1161/JAHA.118.008888.
11. Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014;371(9):818–27.
12. Carey RM, Muntner P, Bosworth HB, Whelton PK. Prevention and control of hypertension. JACC health promotion series. J Am Coll Cardiol. 2018;72(11):1278–93.
13. van der Laan DM, Elders PIM, Booms C, Beckeringh JJ, Nijpels G, Hugtenburg JG. Factors associated with antihypertensive medication non-adherence: a systematic review. J Hum Hypertens. 2017;31(11):687–94.
14. Souza AC, Borges JW, Moreira TM. Quality of life and treatment adherence in hypertensive patients: systematic review with meta-analysis. Rev Saude Publica. 2016;50:71.
15. Abegaz TM, Shehab A, Gebreynohaness EA, Bhagavathula AS, Elnaar AA. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(4):e6541.
16. Alsubbagh MH, Lemstra M, Eunch D, Lia LM, Wilson TW, Watson E, et al. Socioeconomic status and nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Value Health. 2014;17(2):288–96.
17. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013;62(2):218–25.
18. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(4):2159–219.
19. Perkovic V, Rodgers A. Redefining blood-pressure targets—SPRINT starts the marathon. N Engl J Med. 2015;373(22):2175–8.
20. Saqib N, Saqib J, Ahmed T, Khanam MA, Cullen MR. Cardiovascular diseases and type 2 diabetes in Bangladesh: a systematic review and meta-analysis of studies between 1995 and 2010. BMC Public Health. 2012;12:434. https://doi.org/10.1186/1471-2458-112-1434.
21. Chowdhury MZI, Rahman M, Akter T, Akhter T, Ahmed A, Shovon MA, et al. Hypertension prevalence and its trend in Bangladesh: evidence from a systematic review and meta-analysis. Clin Hypertens. 2020;26:10.
22. Islam FM, Bhuyan A, Chakrabarti R, Rahman MA, Kanagasingam Y, Hille Jr. Undiagnosed hypertension in a rural district in Bangladesh: The Bangladesh Population-based Diabetes and Eye Study (BPDES). J Hum Hypertens. 2016;30(4):252–9.
23. Jafar TH, Gandhi M, Jehan I, Naheed A, de Silva HA, Shahab H, et al. Determinants of uncontrolled hypertension in rural communities in South Asia- Bangladesh, Pakistan, and Sri Lanka. Am J Hypertens. 2018;31(11):1205–14.

24. Alam DS, Chowdhury MA, Siddiquee AT, Ahmed S, Niessen LW. Awareness and control of hypertension in Bangladesh: follow-up of a hypertensive cohort. BMJ Open. 2014;4(12):e004983.

25. Chakrabarti R, Finger RP, Lamoureux E, Islam MT, Drani M, Bhuayan MA, et al. Rationale and methodology for a population-based study of diabetes and common eye diseases in a rural area in Bangladesh: Bangladesh Population-based Diabetes and Eye Study (BPDES). Bangladesh J Med Sci. 2015;14(Epub):367–75.

26. Rahman MS, Hanif S, Khatoon F, Iqbal M, Rasheed S, Ahmed T, et al. Knowledge, attitudes and intention regarding mHealth in generation Y: evidence from a population based cross sectional study in Chakaria, Bangladesh. BMJ Open. 2017;7(1):e0116217.

27. Whelton PK, Carey RM, Aronow WS, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127–248.

28. Islam FMA, Lambert EA, Islam SMS, Islam MA, Biswas D, McDonald R, et al. Lowering blood pressure by changing lifestyle through a motivational education program: a cluster randomized controlled trial study protocol. Trials. 2021;22(1):438.

29. Hypertension Study G. Prevalence, awareness, treatment and control of hypertension among the elderly in Bangladesh and India: a multicentre study. Bull World Health Organ. 2001;79(6):490–500.

30. Cheng YH, Chi I, Boey KW, Ko LS, Chou KL. Self-rated economic condition and the health of elderly persons in Hong Kong. Soc Sci Med. 2002;55(8):1415–24.

31. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Rev Esp Cardiol 2019, 72(2):160.

32. Islam JY, Zaman MM, Haq SA, Ahmed S, Al-Quadir Z. Epidemiology of hypertension among Bangladeshi adults using the 2017 ACC/AHA Hypertension Clinical Practice Guidelines and Joint National 7 Guidelines. J Hum Hypertens. 2018;32(10):668–80.

33. Mahmood S, Jalal Z, Hadi MA, Shah KU. Association between attendance at outpatient follow-up appointments and blood pressure control among patients with hypertension. BMC Cardiovasc Disord. 2020;20(1):458.

34. Borzechs AM, Glickman ME, Kader B, Berlowitz DR. The effect of age on hypertension control and management. Am J Hypertens. 2006;19(5):520–7.

35. Vargas CM, Ingram DD, Gillum RF. Incidence of hypertension and educational attainment: the NHANES I epidemiologic followup study, First National Health and Nutrition Examination Survey. Am J Epidemiol. 2000;152(3):272–8.

36. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4(6):393–404.

37. Drieling RL, LaCroix AZ, Beresford SA, Boudreau DM, Kooperberg C, Heckbert SR. Validity of self-reported medication use compared with pharmacy records in a cohort of older women: findings from the women's health initiative. Am J Epidemiol. 2016;184(3):233–8.

38. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta A, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959–68.

39. Nicomen M, Hieermann T, Muller-Riemenschneider F, Thalau F, Roll S, Willich SN. Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil. 2008;15(3):239–46.

40. Katmarzyk PT, Lear SA. Physical activity for obese individuals: a systematic review of effects on chronic disease risk factors. Obes Rev. 2012;13(2):95–105.

41. Owen N, Healy GN, Dempsey PC, Salmon J, Timperio A, Clark BK, et al. Sedentary behavior and public health: integrating the evidence and identifying potential solutions. Annu Rev Public Health. 2020;41:265–87.

42. Clermie RE, Srikanth V, Keith LJ, Davies JE, Sharman JE. Exercise excess pressure and exercise-induced albuminuria in patients with type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol. 2013;308(9):H136–42.

43. Borgi L, Muraki I, Satija A, Willett WC, Rimm EB, Forman JP. Fruit and vegetable consumption and the incidence of hypertension in three prospective cohort studies. Hypertension. 2016;67(2):288–93.

44. Lambert EA, Lambert GW. Stress and its role in sympathetic nervous system activation in hypertension and the metabolic syndrome. Curr Hypertens Rep. 2011;13(3):244–8.

45. Menanga A, Edie S, Nkokie C, Boembbi J, Musa AJ, Mfeukeu UK, et al. Factors associated with blood pressure control amongst adults with hypertension in Yaounde, Cameroon: a cross-sectional study. Cardiovasc Diagn Ther. 2016;6(5):439–45.

46. Sarganas G, Knopf H, Grams D, Neuhauser HK. Trends in antihypertensive medication use and blood pressure control among adults with hypertension in Germany. Am J Hypertens. 2016;29(11):104–13.

47. Group SR, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.

48. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.

49. WHO. National guidelines for management of hypertension in Bangladesh. 2013 https://apps.who.int/iris/handle/10665/279486. Accessed 25 Jun 2021.

50. GHWA. Global Health Workforce Alliance World Health Organisation 2016.